Liberty Corporate Finance advised the management team of Ivent Farma, led by Ervin Veszpremi (CEO), on the transaction.
Located in Barcelona, Invent Farma develops, manufactures and markets generic drugs. It owns and operates manufacturing plants in Spain and comprises three divisions:
- Inke, a manufacturer of active pharmaceutical ingredients (“APIs”) which has a unique expertise in the respiratory area;
- Lesvi, a highly flexible manufacturer of finished dosage forms (“FDFs”) that has capabilities across multiple therapeutic areas; and
- Qualigen, which markets generic drugs in Spain and has a leading and rapidly growing franchise in the central nervous system (“CNS”) field.
Apax Partners will look to support the organic growth of Invent Farma as well as further consolidate the European generics market.
This strategy has already commenced with the acquisition of Germany’s neuraxpharm which completed simultaneously with the Invent Farma transaction.
Ervin Veszprémi, CEO of Invent Farma commented:
“We have enjoyed having Liberty’s outstanding support throughout the transaction. Their exquisite knowledge in this business field provided us with exceptionally good advice during the process. I am very happy with their help, they made it easy for us to understand the pros and the cons for each single step.”
Mick McDonagh, Partner at Liberty Corporate Finance added:
“We are delighted to have supported Ervin, Javier and the rest of the senior management team in this transaction. They have delivered significant growth for Invent Farma over recent years and have built an impressive collection of generic pharmaceuticals businesses. We are also delighted that Invent is our second transaction in Spain in the past 18 months, following on from the idealista transaction in 2015.”